|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EPRS |
Gene summary for EPRS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EPRS | Gene ID | 2058 |
| Gene name | glutamyl-prolyl-tRNA synthetase 1 | |
| Gene Alias | EARS | |
| Cytomap | 1q41 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P07814 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2058 | EPRS | P127T-E | Human | Esophagus | ESCC | 8.78e-12 | 3.02e-01 | 0.0826 |
| 2058 | EPRS | P128T-E | Human | Esophagus | ESCC | 1.47e-49 | 1.91e+00 | 0.1241 |
| 2058 | EPRS | P130T-E | Human | Esophagus | ESCC | 2.47e-70 | 1.85e+00 | 0.1676 |
| 2058 | EPRS | HCC1_Meng | Human | Liver | HCC | 8.18e-81 | 5.19e-01 | 0.0246 |
| 2058 | EPRS | HCC2_Meng | Human | Liver | HCC | 4.22e-37 | 1.98e-01 | 0.0107 |
| 2058 | EPRS | cirrhotic2 | Human | Liver | Cirrhotic | 1.17e-05 | 1.53e-01 | 0.0201 |
| 2058 | EPRS | HCC1 | Human | Liver | HCC | 6.77e-12 | 4.59e+00 | 0.5336 |
| 2058 | EPRS | HCC2 | Human | Liver | HCC | 2.90e-31 | 5.93e+00 | 0.5341 |
| 2058 | EPRS | Pt13.b | Human | Liver | HCC | 1.02e-16 | 2.95e-01 | 0.0251 |
| 2058 | EPRS | Pt14.a | Human | Liver | HCC | 2.17e-04 | 3.64e-01 | 0.0169 |
| 2058 | EPRS | S014 | Human | Liver | HCC | 3.26e-33 | 1.48e+00 | 0.2254 |
| 2058 | EPRS | S015 | Human | Liver | HCC | 2.10e-25 | 1.51e+00 | 0.2375 |
| 2058 | EPRS | S016 | Human | Liver | HCC | 1.45e-34 | 1.56e+00 | 0.2243 |
| 2058 | EPRS | S027 | Human | Liver | HCC | 3.38e-24 | 2.28e+00 | 0.2446 |
| 2058 | EPRS | S028 | Human | Liver | HCC | 2.08e-45 | 2.31e+00 | 0.2503 |
| 2058 | EPRS | S029 | Human | Liver | HCC | 5.62e-39 | 2.55e+00 | 0.2581 |
| 2058 | EPRS | C04 | Human | Oral cavity | OSCC | 1.00e-19 | 1.16e+00 | 0.2633 |
| 2058 | EPRS | C21 | Human | Oral cavity | OSCC | 1.47e-53 | 1.81e+00 | 0.2678 |
| 2058 | EPRS | C30 | Human | Oral cavity | OSCC | 1.19e-28 | 1.24e+00 | 0.3055 |
| 2058 | EPRS | C38 | Human | Oral cavity | OSCC | 1.40e-06 | 1.09e+00 | 0.172 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
| GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
| GO:0032869 | Colorectum | AD | cellular response to insulin stimulus | 72/3918 | 203/18723 | 1.10e-06 | 3.68e-05 | 72 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0071375 | Colorectum | AD | cellular response to peptide hormone stimulus | 95/3918 | 290/18723 | 1.50e-06 | 4.66e-05 | 95 |
| GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
| GO:0006418 | Colorectum | AD | tRNA aminoacylation for protein translation | 19/3918 | 41/18723 | 2.37e-04 | 3.03e-03 | 19 |
| GO:0043039 | Colorectum | AD | tRNA aminoacylation | 19/3918 | 44/18723 | 7.13e-04 | 7.21e-03 | 19 |
| GO:0043038 | Colorectum | AD | amino acid activation | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:2000191 | Colorectum | AD | regulation of fatty acid transport | 14/3918 | 32/18723 | 3.03e-03 | 2.25e-02 | 14 |
| GO:00064181 | Colorectum | SER | tRNA aminoacylation for protein translation | 17/2897 | 41/18723 | 5.75e-05 | 1.35e-03 | 17 |
| GO:00328681 | Colorectum | SER | response to insulin | 65/2897 | 264/18723 | 6.70e-05 | 1.53e-03 | 65 |
| GO:19016531 | Colorectum | SER | cellular response to peptide | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
| GO:00434341 | Colorectum | SER | response to peptide hormone | 93/2897 | 414/18723 | 9.61e-05 | 2.04e-03 | 93 |
| GO:00430391 | Colorectum | SER | tRNA aminoacylation | 17/2897 | 44/18723 | 1.64e-04 | 3.12e-03 | 17 |
| GO:00713751 | Colorectum | SER | cellular response to peptide hormone stimulus | 68/2897 | 290/18723 | 2.20e-04 | 3.89e-03 | 68 |
| GO:00430381 | Colorectum | SER | amino acid activation | 17/2897 | 45/18723 | 2.25e-04 | 3.91e-03 | 17 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EPRS | SNV | Missense_Mutation | c.866N>T | p.Ala289Val | p.A289V | P07814 | protein_coding | deleterious(0) | possibly_damaging(0.735) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EPRS | SNV | Missense_Mutation | c.3355C>T | p.Arg1119Cys | p.R1119C | P07814 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| EPRS | SNV | Missense_Mutation | c.2947G>A | p.Asp983Asn | p.D983N | P07814 | protein_coding | tolerated(0.07) | benign(0.047) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| EPRS | SNV | Missense_Mutation | novel | c.760G>A | p.Glu254Lys | p.E254K | P07814 | protein_coding | tolerated(0.12) | possibly_damaging(0.556) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| EPRS | SNV | Missense_Mutation | c.3753N>A | p.Met1251Ile | p.M1251I | P07814 | protein_coding | deleterious(0.01) | possibly_damaging(0.463) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| EPRS | SNV | Missense_Mutation | c.1058N>T | p.Asp353Val | p.D353V | P07814 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| EPRS | SNV | Missense_Mutation | c.2441N>T | p.Ser814Phe | p.S814F | P07814 | protein_coding | deleterious(0.03) | benign(0.098) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EPRS | SNV | Missense_Mutation | c.2284G>A | p.Asp762Asn | p.D762N | P07814 | protein_coding | tolerated(0.34) | benign(0.327) | TCGA-D8-A27R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| EPRS | SNV | Missense_Mutation | novel | c.3727C>G | p.His1243Asp | p.H1243D | P07814 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| EPRS | insertion | In_Frame_Ins | novel | c.4428_4429insTTACAG | p.Ala1476_Lys1477insLeuGln | p.A1476_K1477insLQ | P07814 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |